Contrast-induced encephalopathy (CIE) is a well-known complication of iodinated contrast agents during angiography and vascular interventions. It can manifest as hemiparesis, cortical blindness, speech changes, Parkinsonism, confusion, seizure, and coma. Most of the reported CIE cases have been transient and reversible. Irreversible fatal CIE cases have been rarely reported. All the fatal CIE cases reported involved the use of ionic high osmolar contrast agents. Here, we document a heretofore unreported fatal CIE after digital subtraction angiography (DSA) using iopamidol, which is a type of non-ionic monomer low osmolar contrast agent. A 71-year-old woman was admitted to our Department of Neurology for tinnitus in the head. The cerebral magnetic resonance angiography (MRA) detected atherosclerotic cerebral arteries and bilateral stenosis of the middle cerebral arteries. The patient underwent DSA for further diagnostic work-up. The total amount of iopamidol used during the procedure was 110 ml. The patient experienced headache during the procedure, followed by dizziness with nausea and vomiting. Despite treatment with anti-oedema medications, her clinical status was gradually deteriorating and ended up with deep coma due to irreversible cerebral oedema which was confirmed by cerebral computed tomography (CT). Finally, the patient died 56 days after the procedure due to irreversible fatal cerebral oedema. This report documents that iopamidol-induced encephalopathy may not always have a benign outcome and can result in irreversible fatal cerebral oedema.
Patients with medically refractory non-acute intracranial artery occlusion (ICAO) are difficult to treat. The optimal intervention for these patients is not known. We evaluated the feasibility and safety of drug-coated balloon (DCB) treatment for non-acute ICAO. Consecutive patients with symptomatic medically refractory atherosclerotic non-acute ICAO from January 2015 to July 2021 who underwent DCB treatment were retrospectively analyzed. The rates of stroke, transient ischemic attack, and death within 30 days and the follow-up results were evaluated. A total of 148 patients were enrolled in this study. The 30-day rate of stroke, transient ischemic attack, and death was 8.8%. During the 25.8 ± 15.8-month clinical follow-up period, the rate of outcome beyond 30 days was 4.7%. In the 66 patients with vessel imaging follow-up, 13.6% (9/66) had restenosis. The present study suggests that DCB dilatation is a feasible and effective alternative in carefully selected patients with symptomatic non-acute ICAO.
18 November 2025 in Frontiers in Cardiovascular Medicine
Tirofiban is a glycoprotein (GP) IIb/IIIa receptor antagonist that inhibits platelet-to-platelet interactions and thrombosis by preventing fibrinogen from binding to platelets. While it has the potential to cause thrombocytopenia and bleeding, instances of severe thrombocytopenia are rare. The question arises whether the concurrent use of tirofiban with other drugs that pose risks to platelets might increase the likelihood of severe platelet depletion. Herein, we present two cases of profound and sudden thrombocytopenia associated with tirofiban use in the treatment of acute progressive stroke. Both patients received ibuprofen for pain relief concomitantly. Drug-induced thrombocytopenia (DITP), a rare but potentially life-threatening adverse effect, occurred. Ibuprofen is a nonsteroidal anti-inflammatory drugs (NSAIDs) with both aspects regarding platelets: function inhibition, responsible for drug-induced thrombocytopenia. We recommend avoiding concomitant use of ibuprofen in patients receiving tirofiban infusion. Alternative analgesics (e.g., acetaminophen/paracetamol) may be considered when pain management is required. If concurrent administration is unavoidable, intensive platelet count monitoring (e.g., every 6–12 h) is imperative during the first 24 h of therapy.